Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Α-Glucosidase and Α-Amylase Inhibition, Molecular Modeling and Pharmacokinetic Studies of New Quinazolinone-1,2,3-Triazole-Acetamide Derivatives Publisher



Yavari A1 ; Mohammadikhanaposhtani M2 ; Moradi S1 ; Bahadorikhalili S3 ; Pourbagher R2 ; Jafari N4 ; Faramarzi MA3 ; Zabihi E2 ; Mahdavi M5 ; Biglar M5 ; Larijani B5 ; Hamedifar H6 ; Hajimiri MH7
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Chemistry Tehran North Branch, Islamic Azad University, Tehran, Iran
  2. 2. Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran
  3. 3. School of Chemistry, College of Science, University of Tehran, Tehran, Iran
  4. 4. Department of Pharmaceutical Biotechnology, Faculty of Pharmacy and Biotechnology Research Center, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran, University of Medical Sciences, Tehran, Iran
  6. 6. CinnaGen Medical Biotechnology Research Center, Alborz University of Medical Sciences, Karaj, Iran
  7. 7. Nano Alvand Company, Avicenna Tech Park, Tehran University of Medical Sciences, Tehran, Iran

Source: Medicinal Chemistry Research Published:2021


Abstract

In this study, a new series of quinazolinone-1,2,3-triazole-acetamide hybrids 8a–m, using by molecular hybridization of the potent α-glucosidase inhibitor pharmacophores, was designed and evaluated against carbohydrate-hydrolyzing enzymes α-glucosidase and α-amylase. All the synthesized compounds with IC50 values in the range of 45.3 ± 1.4 µM to 195.5 ± 4.7 µM were significantly more potent than standard inhibitor against α-glucosidase, while these compounds were not active against α-amylase in comparison to standard inhibitor. Representatively, compound 8a with IC50 = 45.3 ± 1.4 µM was around 17 times more potent than standard inhibitor acarbose (IC50 = 750.0 ± 12.5 µM). The inhibition kinetic analysis of the compound 8a indicated that this compound was a competitive α-glucosidase inhibitor. Molecular modeling analysis confirmed that the most potent inhibitors 8a and 8b well accommodated in the modeled α-glucosidase active site and it was also revealed that these compounds formed stable inhibitor–receptor complexes with the α-glucosidase in comparison to acarbose. In silico pharmacokinetic and toxicity of the most potent compounds were evaluated and obtained results were compared with acarbose. Furthermore, the most potent compounds were also evaluated against human normal cells and no cytotoxicity was observed. © 2021, The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature.
Related Docs
View other Related Docs
1. Synthesis, in Vitro and in Silico Enzymatic Inhibition Assays, and Toxicity Evaluations of New 4,5-Diphenylimidazole-N-Phenylacetamide Derivatives As Potent Α-Glucosidase Inhibitors, Medicinal Chemistry Research (2021)
2. Design, Synthesis, in Vitro, and in Silico Biological Evaluations of Coumarin-Indole Hybrids As New Anti-Α-Glucosidase Agents, BMC Chemistry (2022)
3. New 6-Amino-Pyrido[2,3-D]Pyrimidine-2,4-Diones As Novel Agents to Treat Type 2 Diabetes: A Simple and Efficient Synthesis, Α-Glucosidase Inhibition, Molecular Modeling and Kinetic Study, European Journal of Medicinal Chemistry (2018)
4. Novel Coumarin Containing Dithiocarbamate Derivatives As Potent Α-Glucosidase Inhibitors for Management of Type 2 Diabetes, Medicinal Chemistry (2021)
5. New Biscoumarin Derivatives As Potent Α-Glucosidase Inhibitors: Synthesis, Biological Evaluation, Kinetic Analysis, and Docking Study, Polycyclic Aromatic Compounds (2020)
6. Quinazolinone-Dihydropyrano[3,2-B]Pyran Hybrids As New Α-Glucosidase Inhibitors: Design, Synthesis, Enzymatic Inhibition, Docking Study and Prediction of Pharmacokinetic, Bioorganic Chemistry (2021)
7. Discovery of Novel 4,5-Diphenyl-Imidazol-Α-Aminophosphonate Hybrids As Promising Anti-Diabetic Agents: Design, Synthesis, in Vitro, and in Silico Enzymatic Studies, Bioorganic Chemistry (2023)
8. Pyrano[2,3-B]Chromone Derivatives As Novel Dual Inhibitors of Α-Glucosidase and Α-Amylase: Design, Synthesis, Biological Evaluation, and in Silico Studies, Bioorganic Chemistry (2024)
Experts (# of related papers)
View all Related Experts
Mohammad Ali Faramarzi (20)
Mohammad Mahdavi (20)
Other Related Docs
9. Synthesis, in Vitro and in Silico Screening of 2-Amino-4-Aryl-6-(Phenylthio) Pyridine-3,5-Dicarbonitriles As Novel Α-Glucosidase Inhibitors, Bioorganic Chemistry (2020)
10. Indole-Carbohydrazide Linked Phenoxy-1,2,3-Triazole-N-Phenylacetamide Derivatives As Potent Α-Glucosidase Inhibitors: Design, Synthesis, in Vitro Α-Glucosidase Inhibition, and Computational Studies, BMC Chemistry (2023)
11. Synthesis, Molecular Docking and Α-Glucosidase Inhibitory Activity Study of 2,4,6-Triaryl Pyrimidine Derivatives, Letters in Drug Design and Discovery (2020)
12. Design, Synthesis, and in Silico Studies of Benzimidazole Bearing Phenoxyacetamide Derivatives As Α-Glucosidase and Α-Amylase Inhibitors, Journal of Molecular Structure (2022)
13. New Acridine-9-Carboxamide Linked to 1,2,3-Triazole-N-Phenylacetamide Derivatives As Potent Α-Glucosidase Inhibitors: Design, Synthesis, in Vitro, and in Silico Biological Evaluations, Medicinal Chemistry Research (2020)
14. Design, Synthesis, in Vitro Anti-Α-Glucosidase Evaluations, and Computational Studies of New Phthalimide-Phenoxy-1,2,3-Triazole-N-Phenyl (Or Benzyl) Acetamides As Potential Anti-Diabetic Agents, Scientific Reports (2023)
15. Design, Synthesis, Characterization, Enzymatic Inhibition Evaluations, and Docking Study of Novel Quinazolinone Derivatives, International Journal of Biological Macromolecules (2021)
16. Design, Synthesis, in Vitro, and in Silico Enzymatic Evaluations of Thieno[2,3-B]Quinoline-Hydrazones As Novel Inhibitors for Α-Glucosidase, Bioorganic Chemistry (2022)
17. Design and Synthesis of Novel Quinazolinone-1,2,3-Triazole Hybrids As New Anti-Diabetic Agents: In Vitro Α-Glucosidase Inhibition, Kinetic, and Docking Study, Bioorganic Chemistry (2019)
18. 2,4-Dioxochroman Moiety Linked to 1,2,3-Triazole Derivatives As Novel Α-Glucosidase Inhibitors: Synthesis, in Vitro Biological Evaluation, and Docking Study, Current Organic Chemistry (2020)
19. Design and Synthesis of New Imidazo[1,2-B]Pyrazole Derivatives, in Vitro Α-Glucosidase Inhibition, Kinetic and Docking Studies, Molecular Diversity (2020)
20. Novel N′-Substituted Benzylidene Benzohydrazides Linked to 1,2,3-Triazoles: Potent Α-Glucosidase Inhibitors, Scientific Reports (2023)
21. Coumarins and Gastrointestinal Cancer: A New Therapeutic Option?, Frontiers in Oncology (2021)
22. Imidazo[1,2-C]Quinazolines As a Novel and Potent Scaffold of Α-Glucosidase Inhibitors: Design, Synthesis, Biological Evaluations, and in Silico Studies, Scientific Reports (2023)
23. Design and Synthesis of Novel Quinazolinone-Pyrazole Derivatives As Potential Α-Glucosidase Inhibitors: Structure-Activity Relationship, Molecular Modeling and Kinetic Study, Bioorganic Chemistry (2021)
24. Design, Synthesis, and in Silico Studies of Quinoline-Based-Benzo[D]Imidazole Bearing Different Acetamide Derivatives As Potent Α-Glucosidase Inhibitors, Scientific Reports (2022)